National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Hydroxycarbamide solution (Xromi®). HTA ID: 20020

Hydroxycarbamide (Xromi®) is indicated for the prevention of vaso-occlusive complications of sickle cell disease in patients over two years of age.

 

NCPE Assessment Process Complete
Rapid review commissioned 20/04/2020
Rapid review completed 14/05/2020
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that hydroxycarbamide (Xromi®) not be considered for reimbursement at the submitted price.*

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.

The HSE has approved reimbursement; August 2020.